Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Perl AE, et al. Among authors: tibes r. Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20. Lancet Oncol. 2017. PMID: 28645776 Free PMC article. Clinical Trial.
Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S. Tibes R, et al. Cancer. 2006 Jun 15;106(12):2645-51. doi: 10.1002/cncr.21901. Cancer. 2006. PMID: 16688777 Free article. Clinical Trial.
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
Garcia-Manero G, Tibes R, Kadia T, Kantarjian H, Arellano M, Knight EA, Xiong H, Qin Q, Munasinghe W, Roberts-Rapp L, Ansell P, Albert DH, Oliver B, McKee MD, Ricker JL, Khoury HJ. Garcia-Manero G, et al. Among authors: tibes r. Invest New Drugs. 2015 Aug;33(4):870-80. doi: 10.1007/s10637-015-0242-6. Epub 2015 May 2. Invest New Drugs. 2015. PMID: 25933833 Free PMC article. Clinical Trial.
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Zeidner JF, et al. Among authors: tibes r. Haematologica. 2015 Sep;100(9):1172-9. doi: 10.3324/haematol.2015.125849. Epub 2015 May 28. Haematologica. 2015. PMID: 26022709 Free PMC article. Clinical Trial.
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H. Issa JJ, et al. Among authors: tibes r. Lancet Oncol. 2015 Sep;16(9):1099-1110. doi: 10.1016/S1470-2045(15)00038-8. Epub 2015 Aug 19. Lancet Oncol. 2015. PMID: 26296954 Free PMC article. Clinical Trial.
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).
Ravandi F, Gojo I, Patnaik MM, Minden MD, Kantarjian H, Johnson-Levonas AO, Fancourt C, Lam R, Jones MB, Knox CD, Rose S, Patel PS, Tibes R. Ravandi F, et al. Among authors: tibes r. Leuk Res. 2016 Sep;48:92-100. doi: 10.1016/j.leukres.2016.07.004. Epub 2016 Jul 25. Leuk Res. 2016. PMID: 27544076 Free PMC article. Clinical Trial.
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.
Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G, Jagasia M, Kantarjian HM, Kropf P, Metheny L, Moore JO, Ontiveros E, Purev E, Quiery A, Reddy VV, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Tibes R, Yang DT, Gregory K, Sundar H, Deininger M, Radich JP. Pallera A, et al. Among authors: tibes r. J Natl Compr Canc Netw. 2016 Dec;14(12):1505-1512. doi: 10.6004/jnccn.2016.0162. J Natl Compr Canc Netw. 2016. PMID: 27956535
Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey.
Begna K, Al-Kali A, Elliott M, Foran J, Gangat N, Hogan W, Hook C, Leis J, Litzow M, Mesa R, Palmer J, Pardanani A, Patnaik M, Rivera C, Sproat L, Tibes R, Wolanskyj-Spinner A, Tefferi A. Begna K, et al. Among authors: tibes r. Am J Hematol. 2017 Nov;92(11):E626-E627. doi: 10.1002/ajh.24866. Epub 2017 Aug 17. Am J Hematol. 2017. PMID: 28730596 Free article. No abstract available.
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ. Kantarjian HM, et al. Among authors: tibes r. Lancet Oncol. 2017 Oct;18(10):1317-1326. doi: 10.1016/S1470-2045(17)30576-4. Epub 2017 Aug 24. Lancet Oncol. 2017. PMID: 28844816 Free PMC article. Clinical Trial.
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
Webster JA, Tibes R, Morris L, Blackford AL, Litzow M, Patnaik M, Rosner GL, Gojo I, Kinders R, Wang L, Doyle LA, Huntoon CJ, Karnitz LM, Kaufmann SH, Karp JE, Smith BD. Webster JA, et al. Among authors: tibes r. Leuk Res. 2017 Oct;61:108-116. doi: 10.1016/j.leukres.2017.09.005. Epub 2017 Sep 20. Leuk Res. 2017. PMID: 28957699 Free PMC article. Clinical Trial.
95 results